Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. (NUS) Market Cap

Nu Skin Enterprises, Inc. has a market capitalization of $380.2M.

Financials based on reported quarter end 2025-12-31

Price: $7.90

โ–ฒ 0.25 (3.27%)

Market Cap: 380.20M

NYSE ยท time unavailable

CEO: Ryan S. Napierski

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1996-11-22

Website: https://www.nuskin.com

Nu Skin Enterprises, Inc. (NUS) - Company Information

Market Cap: 380.20M ยท Sector: Consumer Defensive

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

Analyst Sentiment

50%
Hold

Based on 0 ratings

Analyst 1Y Forecast: $0.00

Average target (based on 2 sources)

Consensus Price Target

Low

$11

Median

$11

High

$11

Average

$11

Potential Upside: 39.2%

Price & Moving Averages

Loading chart...

๐Ÿ“˜ Full Research Report

โ„น๏ธ

AI-Generated Research: This report is for informational purposes only.

๐Ÿ“˜ NU SKIN ENTERPRISES INC CLASS A (NUS) โ€” Investment Overview

๐Ÿงฉ Business Model Overview

NU Skin Enterprises operates a direct-sales model in beauty and wellness, with a strong emphasis on consumer products sold through an independent consultant network. The value chain blends product development and sourcing with distribution and customer acquisition driven by a relationship-based sales force. Consultants educate customers, manage repeat purchases, and often recruit additional consultants, creating a two-sided commercial system: consumers receive guided access to products, while consultants gain earning opportunities tied to personal sales and organizational performance. This structure tends to support higher customer retention than purely transactional retail channels because purchasing is reinforced by ongoing contact, usage routines, and community-based incentives.

๐Ÿ’ฐ Revenue Streams & Monetisation Model

Revenue is primarily monetized through product sales to consumers, with a meaningful recurring component arising from replenishment cycles typical of skincare and personal care categories. Although the company sells through a direct-consumer interface (consultant-led order flow), the business behaves economically like a repeat-purchase platform: product usage and routines can drive repeat orders over time, while product assortments and promotional cadences influence purchase frequency and basket composition.

Margin structure is driven by (1) product gross margin (impacted by sourcing costs, manufacturing mix, and channel/promotion intensity), (2) variable sales and distribution costs (linked to consultant compensation and incentive plans), and (3) operating leverage as marketing and overhead can be spread across a larger order base when consultant productivity and retention remain healthy. Because customer acquisition is relationship-mediated, operating discipline and product-market fit are key for sustaining conversion and keeping incremental customer costs from rising faster than revenue.

๐Ÿง  Competitive Advantages & Market Positioning

The main moat is switching costs and behavioral stickiness created by the consultant-led experience and routine-based consumption. Consumers typically develop a repeat purchasing pattern tied to product formulations, education on use, and ongoing recommendations. Switching to alternative brands is not purely a price comparison; it also requires re-establishing a new regimen and losing the guidance and trust embedded in the consultant relationship.

A secondary moat is distribution know-how and organizational scale within direct selling. Competitors can copy product claims and even similar pricing, but building a comparable consultant network at consistent productivity takes time and operational capability. NU Skinโ€™s ability to recruit, train, and retain consultantsโ€”while aligning incentives with sustainable consumer demandโ€”can act as a durable advantage.

Additionally, the company benefits from intangible assets such as brand recognition in beauty/wellness and proprietary formulation development, which can support differentiation in product efficacy perceptions and reduce churn versus less-established brands.

๐Ÿš€ Multi-Year Growth Drivers

Over a five- to ten-year horizon, growth is supported by secular demand for skincare, anti-aging, and wellness-oriented routines, where consumers increasingly value product guidance and tailored recommendations. TAM expansion is driven by continued global penetration of premium personal care and by the substitution of traditional retail and mass beauty toward guided channels that emphasize product education and ongoing engagement.

For NU Skin specifically, multi-year growth hinges on maintaining consultant productivity and expanding active customers in addressable geographies. Additional drivers include category expansion through new product introductions, improved mix through higher-value SKUs, and the ability to scale repeat purchases by reinforcing routine-based usage. The companyโ€™s direct selling model can also benefit from demographic and lifestyle trends that favor self-improvement and โ€œproblem-solutionโ€ product narratives, provided regulatory and compliance requirements are met consistently.

โš  Risk Factors to Monitor

Key structural risks include:

  • Regulatory and compliance exposure: Direct selling and beauty/wellness products face scrutiny related to marketing claims, compensation practices, and consumer protection. Changes in enforcement intensity or claim standards can pressure demand and increase compliance costs.
  • Channel model sensitivity: Consultant retention and recruiting cycles can affect revenue stability. If consultant productivity declines, sales growth may slow even when consumer category demand remains intact.
  • Product and reputation risk: Quality issues, ingredient controversies, or unmet consumer expectations can raise returns, reduce repeat purchase rates, and impair brand equity.
  • Competitive intensity: Beauty and wellness categories are crowded, with fast-follow competitors leveraging influencer ecosystems and retail scale. Without disciplined product differentiation and customer experience, switching costs can weaken.
  • Manufacturing and sourcing constraints: Ingredient and packaging cost volatility, supply chain disruptions, or unfavorable manufacturing mix can compress gross margins.
  • Technology and distribution disruption: Digital-first beauty commerce and AI-enabled personalization could alter how consumers discover products. NU Skin must preserve the consultant relationship while enhancing digital reach and conversion efficiency.

๐Ÿ“Š Valuation & Market View

The market typically values this sector on a mix of revenue durability, margin sustainability, and growth visibility rather than purely on short-term earnings power. Investors often anchor on metrics such as EV/EBITDA and P/S for consumer/beauty distribution models with repeat behavior, adjusting for (1) the quality of revenue (repeat vs. one-time), (2) the cost structure of distribution and incentives, and (3) evidence that customer retention remains resilient through product cycles.

Drivers that tend to move valuation multiples include credible improvements in operating leverage, stabilization or growth in active customer trends, and demonstrated capability to expand higher-margin products without over-relying on aggressive promotional incentives. Conversely, valuation pressure can arise when regulatory issues, consultant attrition, or margin compression reduce the durability of cash flows.

๐Ÿ” Investment Takeaway

NU Skinโ€™s long-term investment case rests on a repeat-purchase consumer model supported by consultant-led engagement that creates durable switching costs and behavioral stickiness. The companyโ€™s competitive position is reinforced by distribution scale and operational know-how that are difficult to replicate quickly. The primary debate for investors is sustainability: whether NU Skin can maintain consultant productivity and compliant, credible product differentiation while navigating regulatory scrutiny and intensifying competitive dynamics in beauty and wellness.


โš  AI-generated โ€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"As of December 31, 2025, Nu Skin Enterprises (NUS) showed a revenue of $370.32M and a net income of $14.49M, translating to an EPS of $0.30. The company's total assets are valued at $1.41B, with total liabilities at $600.07M, indicating a strong equity position of $805.24M. NUS generated an operating cash flow of $16.62M, yielding a free cash flow of approximately $5.86M after capital expenditures. The company announced a consistent dividend payout of $0.06 across four separate quarters in 2025, although recent market performance reveals a decline of 2.45% over the past year, with a significant drop of 41.98% over the last six months. Despite the negative market sentiment, fundamentals show stability. The overall valuation aligns with a target price of $11.00, suggesting upside potential from the current trading price of $7.16. However, the negative one-year price change reflects challenges in performance that investors should consider."

Revenue Growth

Neutral

Revenue of $370.32M shows a stable position, but lacks significant growth.

Profitability

Fair

Net income of $14.49M indicates moderate profitability but low EPS.

Cash Flow Quality

Neutral

Positive operating cash flow and free cash flow demonstrate reasonable cash management.

Leverage & Balance Sheet

Positive

Strong equity position with total equity at $805.24M and manageable debt levels.

Shareholder Returns

Caution

Despite dividend payments, overall shareholder returns are impacted negatively by a declining stock price.

Analyst Sentiment & Valuation

Neutral

Current price provides a potential for significant upside against target price.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered Q4 and FY 2025 largely โ€œon-plan,โ€ with adjusted EPS of $0.29 in Q4 and $1.27 for the year (~51% growth), supported by gross margin strength in the core (core gross margin +80 bps full-year; +100 bps in Q4) and operating margin expansion (+140 bps adjusted to 6.7%). However, the Q&A revealed execution timing and monetization uncertainty: Prism IOโ€™s >100,000 device placement target does not yet come with quantified revenue conversion because subscription uptake is โ€œso earlyโ€ (only a month into learning). India is the other major lever, but hurdles are concreteโ€”high import duties requiring local manufacturing, complex logistics, and digital infrastructure; management deliberately forecasts conservatively for 2026 since formal launch is late 2026. Analyst pressure focused on โ€œrevenue guideโ€ realism and India bull/bear timing; management pointed to stronger Q3โ€“Q4 effects and conservative 2026 modeling. Net: confidence on transformation, but near-term EPS is constrained by the step-up in tax rate assumption to 35% vs 2025โ€™s R&D credit benefit.

AI IconGrowth Catalysts

  • Prism IO intelligent wellness platform launch on track for full consumer launch in the back half of 2026 (device placement and subscription monetization model)
  • AI-powered intelligence database applications (intelligent scoring, insights, and product recommendations) to support recurring/subscription revenue
  • Expansion into India via premarket operations started mid-November 2025; formal market opening anticipated late 2026
  • Tru Face premium skincare line reformulated/re-staged with sustainable packaging; rollout momentum globally

Business Development

  • India go-to-market includes partnership with Infosys for digital-first infrastructure
  • India operating model includes localized product portfolio, modified compensation plan, and planned local manufacturing (import duties cited as key driver)
  • Evaluation of LifeDNA opportunities to maximize ROI (mentioned as an item within RISE segments strategy)

AI IconFinancial Highlights

  • Q4 revenue: $370,000,000 (within guidance range); FX headwind of ~$1,000,000
  • Q4 EPS (adjusted non-GAAP): $0.29, in line with expectations
  • Q4 gross margin: 70.7% vs 71.4% prior year; decrease primarily from revenue mix (RISE entities and Nu Skin segments)
  • Core Nu Skin Q4 gross margin: 77.6%, up 100 bps YoY
  • Q4 selling expense: 35.5% vs 37.1% prior year (optimization/mix effects noted); core Nu Skin selling expense: 40.8% (consistent)
  • Q4 operating margin: 6.3%
  • Full-year adjusted EPS: $1.27 vs $0.84 prior year (~51% growth); drivers included gross margin expansion, selling expense optimization, and disciplined G&A
  • Full-year revenue: $1.49B (within original guidance); FX headwind ~$13.4M
  • Full-year core Nu Skin gross margin: 77.4%, up 80 bps YoY
  • Adjusted operating margin: 6.7% vs 5.3% prior year (+140 bps)
  • Tax: R&D tax credit reduced tax expense by ~$8.1M; full-year reported effective tax rate 18.8%
  • 2026 guidance tax assumption: 35% expected tax rate; management attributed EPS pressure despite operating margin improvement due to below-the-line tax impacts
  • Gross margin modeling: management referenced five consecutive quarters of gross margin expansion up to Q4 (Q4 down due to higher promotional period); expects ability to continue expansion with inventory/distribution/supply chain moves
  • 2026 growth modeling for revenue: ~+1% on high end of guidance and ~-9% on low end, based on product timing into back half (exit stronger in Q3-Q4)

AI IconCapital Funding

  • Ended Q4 with cash of ~$240,000,000
  • Reduced outstanding debt to ~$224,000,000 (expanded net cash position)
  • Cash flow from operations (full year): $80.3M
  • Capital returned to shareholders in 2025: ~$11.0M dividends and ~$20.0M share repurchases
  • Remaining authorization under buyback program: ~$142.3M

AI IconStrategy & Ops

  • Switching costs acknowledged in 2025 into early 2026 from realigning company/channel business practices during transformation
  • Prism IO build-out of intelligent wellness and AI-backed intelligence database underway; device placements aimed to be scaled in 2026
  • Prism IO unit plan: target placement of >100,000 devices by end of 2026 (device economics cited; subscription uptake still being learned)
  • India operational hurdles cited: local manufacturing focus due to high import duties; logistics across a diverse market; digital-first infrastructure readiness
  • Distribution/supply chain moves and inventory positioning expected to support continued gross margin expansion in 2026
  • Selling expense guidance anchor: core selling expense targeted to remain around 40% (range commentary: 40โ€“42% depending on events; target 40โ€“41%)

AI IconMarket Outlook

  • 2026 revenue guidance: $1.35B to $1.50B; FX headwind $13Mโ€“$15M (~1%)
  • 2026 EPS guidance (adjusted non-GAAP): $0.80 to $1.20; expected tax rate 35%
  • Q1 2026 revenue guidance: $320M to $340M; FX headwind ~1%; Q1 reported EPS expected $0.10 to $0.20 (Q1 seasonally lowest quarter)
  • Prism IO commercialization timing: placement by leaders in first half; full consumer launch towards the back half of 2026; stronger back-half forecast referenced for Q3-Q4 2026
  • India revenue impact stance: formal launch late 2026; management tailored/cautious revenue forecasting for 2026 and indicated upside assessed further into 2027

AI IconRisks & Headwinds

  • Prism IO: subscription uptake is early-stage and not yet quantified for revenue guidance; conversion timing risk tied to full consumer launch and device placement-to-subscription monetization
  • India: key operational risks include import duties (driving need for local manufacturing), logistics across diverse geography, and digital infrastructure readiness; additionally longer sales/activation cycles due to consumers being aspirational but financially conservative
  • Q4 gross margin pressure: Q4 down 70 bps vs prior year (70.7% vs 71.4%) due to higher promotional period and unfavorable mix (RISE/Nu Skin mix effects)
  • Q4 core gross margin rise (+100 bps) offset by consolidated margin decline from mix
  • Tax headwind: 2025 benefited from R&D tax credit (18.8% effective tax rate reported); 2026 guidance assumes 35% tax rate, pressuring EPS even with operating margin improvement
  • Revenue growth trajectory risk in 2026: guidance implies potential -9% YoY at low end driven by timing of product introductions in back half

Sentiment: MIXED

Note: This summary was synthesized by AI from the NUS Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
๐Ÿ“

SEC Filings (NUS)

ยฉ 2026 Stock Market Info โ€” Nu Skin Enterprises, Inc. (NUS) Financial Profile